Autologous lymphokine-activated killer cells (LAK: polyclonal fractions of NK and T cells) were activated ex vivo in IL-2 and re-infused into melanoma and renal cell carcinoma patients, followed by adjuvant high dose IL-2 (214). The gene discussed is IL2; the disease is renal cell carcinoma.